Academic Press Mitochondrial Neuropathies: Volume 145 (International Review of Neurobiology, Volume 145)

Product Description There is growing evidence that nerve damage caused by a variety of conditions shares a common pathogenic mechanism involving mitochondrial dysfunction. This book brings together experts in a range of diseases that damage the nervous system to present the role of mitochondrial dysfunction in their particular field. Diverse expertise of contributors Timely bringing together of fields to highlight a common pathogenic mechanism Focus on role of mitochondria in diverse neuropathies Review Highlights mechanisms that are common to otherwise diverse conditions and identifies therapeutic approaches that broaden clinical applications About the Author Nigel Calcutt, Ph.D. is a Professor in the Department of Pathology at the University of California, San Diego. Dr. Calcutt was spawned and bred in the Black Country of England and took both his B.Sc. in Zoology and Ph.D. Physiology and Pharmacology at Nottingham University, England. Following post-doctoral research at St. Bartholomew’s Hospital, London and at the University of California San Diego, he was appointed to the faculty of the Department of Pathology at UCSD in 1993. Dr. Calcutt first began studying nerve damage caused by diabetes as an undergraduate, with a largely unsuccessful, but nevertheless entertaining, attempt to generate diabetic chickens. Undeterred by the paucity of pre-diabetic poultry, he has continued to investigate mechanisms of diabetic neuropathy and neuropathic pain throughout his career, with a particular interest in developing therapies than can be translated to clinical use. He is also a co-founder of the biotechnology company WinSanTor Inc. and the non-profit organization Diabetes Research Connection. Paul Fernyhough, Ph.D. was born and educated in East London, UK, and took his B.Sc. degree in Biological Sciences at the University of Essex. He then studied for his PhD in biochemistry in the Department of Biochemistry at University of Sheffield in the UK, followed by postdoctoral research at Colorado State University, Kings College London and as a Wellcome Trust Postdoctoral Fellow at St Bartholomew’s Medical College. All of these positions spanned 1985-1998. Dr. Fernyhough was then appointed as a fully tenured lecturer in the School of Biological Sciences at the University of Manchester (1998-2004). Dr. Fernyhough came to Winnipeg in 2004 and, while frequently half-frozen, has helped establish the neuroscience research group at St Boniface Hospital Research Centre with strong links with the Department of Pharmacology & Therapeutics at the University of Manitoba. Dr. Fernyhough’s general research interest is in the cell biology underlying neurodegenerative disorders of the peripheral and central nervous systems with a focus on the impact of diabetes. He is currently Professor and Head of the Department Pharmacology and Therapeutics at the University of Manitoba and Director of the Division of Neurodegenerative Diseases at St Boniface Hospital Research Centre, Winnipeg, Canada. He is also a co-founder of the biotechnology company WinSanTor Inc.